If patients with COPD need to be vaccinated against pneumococcal infection, preference should be given to PCV13 monovaccination. Short-term observations have shown that the sequential use of pneumococcal conjugate and polysaccharide vaccines is redundant and gives no additional benefit to patients with COPD. However, the sequential application of both vaccines may have additional advantages in the long term.

Introduction: Anti-influenza vaccination of pregnant women using a subunit vaccine is an effective method to prevent pregnancy complications and fetal disorders. The efficacy of immunoadjuvant vaccines, as well as the production of IgG antibodies depending on the vaccination trimester requires further investigation. Materials and Methods: 48 mothers were vaccinated against influenza in the II and III trimesters. Grippol plus vaccine was used. Each dose of the vaccine contains antigens of A and B strains and adjuvant Polyoxidonium 500 µg. Hemagluttinine-inhibiting antibodies level (HIAb) were evaluated in sera of mothers and babies at different time points after vaccination using a standard reaction of hemagglutination inhibition, in accordance with criteria developed by the committee for proprietary medicinal products (CPMP). Results: Within 1 month after vaccination, the seroprotection rate against all influenza strains was above the threshold level of 140 in more than 70% of pregnant women. After delivery, the seroprotection level in the group vaccinated in the III trimester was similar for A/California/7/2009/H 1 N 1 /v and А/H 3 N 2 strains, and differed for B strain. The percentage of infants with seroprotection was 55.5%-59.3%, while in their mothers, the respective value was 74.1%-81.5% (p<0.05). Within 3 months, the number of infants with seroprotection against influenza strains in mother-infant pairs was decreased: A/California/7/2009/H 1 N 1 /v, А/H 3 N 2 , B. In infants and the seroprotection level disappeared completely by 6 months. The time of vaccination of pregnant women had no effect on these parameters. In mothers, the protective levels against vaccine strains were found in 46.2%-65.4% of cases after delivery. Conclusion: Vaccination of pregnant women in the II and III trimesters using Grippol plus results in production of antibodies at levels complying with CPMP criteria. No difference in production and transplacental transfer of IgG antibodies against influenza was found in mother-infant pairs vaccinated in different trimesters of pregnancy.

1 Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова РАМН, Москва, Российская Федерация 2 Ульяновский государственный университет, Российская Федерация 3 Научно-исследовательский институт гриппа, Санкт-Петербург, Российская Федерация IgE-ответ после введения пандемической вакцины штамма А/California/7/2009 (Н 1 N 1 )v В статье представлена оценка изменения общих и аллергоспецифических IgE-антител у 70 здоровых волонтеров, привитых вакциной гриппозной субъединичной штамм А/California/7/2009/(H 1 N 1 ) v. Показано, что вакцина безопасна. Установлено, что двукратное введение вакцины не сопровождается нарастанием титра IgE-антител к тканевым компонентам куриного яйца. Также отмечено, что введение препарата сопровождается снижением общего IgE у лиц с исходно повышенным показателем. this vaccine was shown. Repeated second dose administration is not accompanied by increase in IgE-antibodies to egg components. Vaccine injection results in decrease of total IgE in patients with elevated IgE at baseline.

Background: Possibility to control immune system by regulating the activity of Dendritic Cells (DC) with the help of vaccines or other immunobiological drugs opens great prospects for infectious, oncological and autoimmune control. The aim of this study was to evaluate in vitro the effect of adjuvant subunit and non-adjuvant split influenza vaccines on maturation of DCs from human bone marrow. Methods: From bone marrow cells of healthy volunteers, DCs were obtained using rGM-CSF and IL-4. On the 8th day of cultivation, 10μl of vaccines against influenza were introduced into the culture of Immature DCs (i-DCs): a non-adjuvant split vaccine (Vaxigripp, Sanofi Pasteur) and an immunoadjuvant subunit vaccine (Grippol plus, Petrovax), as well as immunomodulator Polyoxidonium. Results: Insertion of influenza vaccines into i-DC culture induced the acquisition by DCs typical morphological signs of maturation. DCs became large with eccentrically located of irregular shape nucleus, densified cytoplasm, numerous processes. By immunophenotypic examination decrease in monocyte/macrophage pool, cells with expression of CD34 immaturity marker, increase in expressing CD11c/CD86 costimulatory molecules and CD83 terminal differentiation molecules were observed. Although Polyoxidonium caused a decrease in number of CD11c/CD14 cells (18, 5%), but compared to vaccines, its activity was lower (p<0, 05). Grippol plus more actively induced differentiation of TLR2 and TLR8 expressing cells, whereas Vaxigripp-expression of TLR4 and TLR8 on DCs. Conclusion: The possibility of using in vitro model of DCs obtained from human bone marrow cells by cytokine stimulation for examination of the ability of influenza vaccines to induce DC maturation processes has been demonstrated.